CA2316886A1 - Beneficial agent delivery system with membrane plug - Google Patents

Beneficial agent delivery system with membrane plug Download PDF

Info

Publication number
CA2316886A1
CA2316886A1 CA002316886A CA2316886A CA2316886A1 CA 2316886 A1 CA2316886 A1 CA 2316886A1 CA 002316886 A CA002316886 A CA 002316886A CA 2316886 A CA2316886 A CA 2316886A CA 2316886 A1 CA2316886 A1 CA 2316886A1
Authority
CA
Canada
Prior art keywords
capsule
beneficial agent
membrane plug
delivery system
plug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002316886A
Other languages
French (fr)
Other versions
CA2316886C (en
Inventor
Guohua Chen
Keith E. Dionne
Lawton Hom
Scott D. Lautenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Alza Corporation
Guohua Chen
Keith E. Dionne
Lawton Hom
Scott D. Lautenbach
Intarcia Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation, Guohua Chen, Keith E. Dionne, Lawton Hom, Scott D. Lautenbach, Intarcia Therapeutics, Inc. filed Critical Alza Corporation
Publication of CA2316886A1 publication Critical patent/CA2316886A1/en
Application granted granted Critical
Publication of CA2316886C publication Critical patent/CA2316886C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

An osmotic delivery system for controlled delivery of a beneficial agent includes an implant capsule containing a beneficial agent and an osmotic agent which swells on contact with water causing the release of the beneficial agent over time. The osmotic delivery system has a membrane plug which allows water to pass through the plug from an exterior of the capsule while preventing the compositions within the capsule from passing out of the capsule. A delivery rate for delivery of the beneficial agent from the implant capsule is controlled by varying a core diameter of the membrane plug within a constant diameter capsule. The membrane plug has a variable water permeation rate depending on an extent to which the membrane plug is constrained by the capsule walls.
CA002316886A 1997-12-30 1998-07-24 Beneficial agent delivery system with membrane plug Expired - Lifetime CA2316886C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7001197P 1997-12-30 1997-12-30
US60/070,011 1997-12-30
PCT/US1998/014814 WO1999033449A1 (en) 1997-12-30 1998-07-24 Beneficial agent delivery system with membrane plug

Publications (2)

Publication Number Publication Date
CA2316886A1 true CA2316886A1 (en) 1999-07-08
CA2316886C CA2316886C (en) 2007-09-25

Family

ID=22092567

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002316886A Expired - Lifetime CA2316886C (en) 1997-12-30 1998-07-24 Beneficial agent delivery system with membrane plug

Country Status (17)

Country Link
US (1) US6113938A (en)
EP (2) EP1041974B1 (en)
JP (1) JP4494629B2 (en)
KR (1) KR100568917B1 (en)
AR (1) AR013256A1 (en)
AT (2) ATE342051T1 (en)
AU (1) AU8493998A (en)
CA (1) CA2316886C (en)
CY (1) CY1112506T1 (en)
DE (1) DE69836149T2 (en)
DK (1) DK1736145T3 (en)
ES (2) ES2273427T3 (en)
HK (1) HK1031331A1 (en)
PT (2) PT1736145E (en)
TW (1) TW381033B (en)
WO (1) WO1999033449A1 (en)
ZA (1) ZA986627B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
WO1999033446A1 (en) * 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
WO2002036072A2 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
CA2434156A1 (en) 2000-12-29 2002-07-25 Bausch & Lomb Incorporated Sustained release drug delivery devices
DE60130928T2 (en) * 2001-01-03 2008-07-17 Bausch & Lomb Inc. DEVICE FOR DELAYED ACTIVE INGREDIENT RELIEF WITH COATED MEDICATION CORE
US6756058B2 (en) * 2001-01-03 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices with multiple agents
US7163688B2 (en) * 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
US20030064095A1 (en) * 2001-09-14 2003-04-03 Imedd, Inc. Microfabricated nanopore device for sustained release of therapeutic agent
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US7074423B2 (en) * 2002-06-17 2006-07-11 Alza Corporation Osmotic delivery system with early zero order push power engine
US20040059228A1 (en) * 2002-09-23 2004-03-25 Scimed Life Systems, Inc. Systems and methods for flushing catheters
MXPA05004593A (en) * 2002-10-29 2005-07-26 Alza Corp Stabilized, solid-state polypeptide particles.
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
BR0317421A (en) * 2002-12-19 2005-11-08 Alza Corp Stable non-aqueous single phase gels and formulations for release from an implantable device
AR043811A1 (en) * 2003-03-31 2005-08-17 Alza Corp NON-WATERPROOF SINGLE PHASE VEHICLES AND FORMULATIONS USING THESE VEHICLES
NZ542779A (en) * 2003-03-31 2009-02-28 Intarcia Therapeutics Inc Osmotic pump with means for dissipating internal pressure by allowing osmotic material to be ejected from the container above a set internal pressure
CL2004000697A1 (en) * 2003-03-31 2005-05-20 Alza Corp OSMOTIC ADMINISTRATION DEVICE THAT INCLUDES: A RESERVE, AN OSMOTIC COMPOSITION, DRUG FORMULATION, AND A PRE-CHARGED MEMBRANE THAT INCLUDES A SEMIPERMEABLE MATERIAL AND A SELECTED POLYETHER LIQUID MATERIAL
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
AU2004233997C1 (en) 2003-04-29 2014-01-30 Massachusetts Institiute Of Technology Methods and devices for the sustained release of multiple drugs
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20090208540A1 (en) * 2003-08-11 2009-08-20 Indevus Pharmaceuticals, Inc. Implantable device for the delivery of naltrexone and methods of use thereof
US7241457B2 (en) 2003-09-30 2007-07-10 Alza Corporation Osmotically driven active agent delivery device providing an ascending release profile
AU2004287402A1 (en) * 2003-10-31 2005-05-19 Alza Corporation Osmotic pump with self-retaining, fast-start membrane plug
JP2007526792A (en) * 2003-11-06 2007-09-20 アルザ・コーポレーシヨン Modular inhalation rate reducer for use with implantable osmotic pumps
US20050175701A1 (en) * 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US8299025B2 (en) 2005-02-03 2012-10-30 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20060263433A1 (en) * 2005-02-03 2006-11-23 Ayer Rupal A Suspension formulation of interferon
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US20070027105A1 (en) * 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US7790671B2 (en) * 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain
KR101106510B1 (en) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 Two-piece, internal-channel osmotic delivery system flow modulator
KR101200728B1 (en) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 Osmotic delivery system and piston assemblies
FI7960U1 (en) * 2007-04-27 2008-07-28 Bayer Schering Pharma Oy Membrane shell for an implantable dosing system
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN102202646A (en) * 2008-09-30 2011-09-28 Endo药物方法有限公司 Implantable device for the delivery of risperidone and methods of use thereof
WO2010039643A1 (en) * 2008-09-30 2010-04-08 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of histrelin and methods of use thereof
CN106880596A (en) * 2008-10-15 2017-06-23 精达制药公司 Highly enriched drug particles, preparation, supensoid agent and its application
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
ES2632431T3 (en) 2009-10-30 2017-09-13 Ntf Therapeutics, Inc. Enhanced Neurturin Molecules
US8038650B2 (en) * 2010-02-22 2011-10-18 Microsert Ltd. Slow release liquid drug delivery device
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
WO2011139799A2 (en) 2010-04-27 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
EP2563912B1 (en) 2010-04-29 2018-09-05 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
WO2011140135A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CN103096925A (en) 2010-05-03 2013-05-08 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-tRNA synthetases
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
CN102985103A (en) 2010-05-04 2013-03-20 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
JP6027965B2 (en) 2010-05-17 2016-11-16 エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of leucyl-tRNA synthetase
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
AU2011261486B2 (en) 2010-06-01 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-tRNA synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
EP2608801B1 (en) 2010-08-25 2019-08-21 aTyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103717210B (en) * 2011-06-15 2018-04-13 友霖生技医药股份有限公司 Multiple field capsule and its manufacture method
EP2861522A1 (en) * 2012-06-14 2015-04-22 Ceramatec, Inc Apparatus and method for delivering beneficial liquids at a consistent rate
CN105101979B (en) 2012-12-21 2021-10-08 安斯泰来再生医药协会 Method for preparing platelets from pluripotent stem cells and composition thereof
JP6564369B2 (en) 2013-12-09 2019-08-21 デュレクト コーポレイション Pharmaceutically active agent conjugates, polymer conjugates, and compositions and methods involving them
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
MX2018005689A (en) 2015-11-05 2018-08-01 Massachusetts Gen Hospital Intrathecal delivery of nucleic acid sequences encoding abcd1 for treatment of adrenomyeloneuropathy.
BR112018073511A2 (en) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. glucagon receptor selective polypeptides and methods of use
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2017345724B2 (en) 2016-10-20 2024-04-18 Peptron, Inc. Methods of delivering a neuroprotective polypeptide to the central nervous system
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
AU2018231249A1 (en) 2017-03-08 2019-09-26 Intarcia Therapeutics, Inc Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
CN113195524A (en) 2018-10-11 2021-07-30 因塔西亚治疗公司 Human amylin analog polypeptides and methods of use
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3732865A (en) * 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US3995632A (en) * 1973-05-04 1976-12-07 Alza Corporation Osmotic dispenser
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4243030A (en) * 1978-08-18 1981-01-06 Massachusetts Institute Of Technology Implantable programmed microinfusion apparatus
US4373527B1 (en) * 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
US4340054A (en) * 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4552561A (en) * 1982-12-23 1985-11-12 Alza Corporation Body mounted pump housing and pump assembly employing the same
US4639244A (en) * 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
GB9027422D0 (en) * 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5456679A (en) * 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
ES2246004T3 (en) 1996-02-02 2006-02-01 Alza Corporation PROLONGED RELEASE OF AN ACTIVE AGENT USING AN IMPLANTABLE SYSTEM.
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
DK1041975T3 (en) * 1997-12-22 2002-11-04 Alza Corp Speed-controlling membranes for controlled drug delivery devices

Also Published As

Publication number Publication date
DE69836149D1 (en) 2006-11-23
AU8493998A (en) 1999-07-19
PT1041974E (en) 2007-01-31
WO1999033449A1 (en) 1999-07-08
ATE342051T1 (en) 2006-11-15
JP4494629B2 (en) 2010-06-30
EP1041974A1 (en) 2000-10-11
KR20010033782A (en) 2001-04-25
ATE537818T1 (en) 2012-01-15
PT1736145E (en) 2012-03-16
US6113938A (en) 2000-09-05
TW381033B (en) 2000-02-01
ZA986627B (en) 1999-03-05
JP2001527035A (en) 2001-12-25
EP1041974B1 (en) 2006-10-11
EP1736145B1 (en) 2011-12-21
KR100568917B1 (en) 2006-04-07
DK1736145T3 (en) 2012-04-10
HK1031331A1 (en) 2001-06-15
ES2378675T3 (en) 2012-04-16
CA2316886C (en) 2007-09-25
EP1736145A3 (en) 2007-09-12
CY1112506T1 (en) 2015-12-09
AR013256A1 (en) 2000-12-13
DE69836149T2 (en) 2007-08-16
ES2273427T3 (en) 2007-05-01
EP1736145A2 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
CA2316886A1 (en) Beneficial agent delivery system with membrane plug
CA2316976A1 (en) Osmotic delivery system with membrane plug retention mechanism
CA2297801A1 (en) Osmotic delivery system with semipermeable plug
AU6136199A (en) Dosage form comprising therapeutic formulation
CA2324493A1 (en) Controlled release oral tablet having a unitary core
ATE287260T1 (en) FORMULATION WITH A PREFORMED OPENING FOR CONTROLLED RELEASE
CA2196777A1 (en) Powdered biocidal compositions
AU5187796A (en) Delivery of substance to the mouth
WO1996041621A3 (en) Osmotic-delivery devices having vapor-permeable coatings
EP1166866A3 (en) Encapsulated chemicals for use in controlled time release applications
GR3034362T3 (en) Osmotic devices having vapor-permeable coatings
IL108691A0 (en) Ph-triggered osmotic bursting delivery devices
ZA200400453B (en) Osmotic implant with membrane and membrane retention means
MX9605646A (en) Prolonged liberation niphedipine compound.
CA2402637A1 (en) Valve for osmotic devices
EP0606790A3 (en) Subject specific,word/phrase selectable, message delivering doll or action figure.
CA2224996A1 (en) Water swellable compositions
CA2148837A1 (en) Delivery Device Having Encapsulated Excipients
WO2002024174A3 (en) Sustained release composition containing clarithromycin
CA2315074A1 (en) Chemical feeder
CA2148625A1 (en) Ink eradicator system
CA2300935A1 (en) Composition, device and method of using
HUT75029A (en) Systems for controlled release of pilocarpine, and semipermeable capsule containing the active ingredient
AU1789301A (en) Osmotic dosage form comprising first and second
KR880005944A (en) Osmotic Continuous Dispensing Oral Delivery System

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180724